Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects
Качественная клиническая практика, 2018 Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system.
D. Yu. Belousov, E. V. Afanasyeva
doaj
Management of feline diabetes mellitus: update and challenges [PDF]
, 2017 PòsterJun
Caparrós Vallcorba, Cristina +1 more
core
Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes?
Journal of DiabetesBackground Rebound hyperglycemia following the resolution of diabetic ketoacidosis (DKA) is common in pediatric patients with type 1 diabetes, increasing the risk of recurrent DKA and complicating the transition to subcutaneous insulin.
Rebecca Ohman‐Hanson +4 more
doaj +1 more source
Recomendaciones del Grupo GARIN para el manejo de pacientes no críticos con diabetes o hiperglucemia de estrés y nutrición artificial [PDF]
, 2012 Background & aims: By means of this update, the GARIN working group aims to define its position regarding the treatment of patients with diabetes or stress hyperglycaemia and artificial nutrition.
García Almeida, J.M. +9 more
core
Concentrated insulins: the new basal insulins
Therapeutics and Clinical Risk Management, 2016 Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj
A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]
, 2017 Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core +1 more source
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Vascular Health and Risk Management, 2015 Joshua J Joseph, Thomas W Donner Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Cardiovascular disease is the leading cause of mortality in type 2 ...
Joseph JJ, Donner TW
doaj
Emulating a Randomized Controlled Trial of Long-Acting Insulins and Cardiovascular Events Using Real-World Data for Patients With Type 2 Diabetes. [PDF]
Pharmacoepidemiol Drug SafWang W +5 more
europepmc +1 more source